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We report a patient with metastatic clear-cell renal cell carcinoma (mRCC) who presented with primary
tumor in situ in the left kidney and metastases to bone, liver, lungs, and brain. After over 5 years of
sunitinib therapy and subsequent cytoreductive left nephrectomy, the patient achieved radiographic
complete response (CR) and had pathologic CR in the nephrectomy specimen. Durable clinical and
pathological CRs are possible with targeted agents, even with primary tumor in situ and widely
disseminated metastases. Ongoing research will deﬁne the optimal duration of systemic therapy in
exceptional responders and identify the molecular determinants of response and resistance.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Targeted agents includingmulti-tyrosine kinase inhibitors (TKIs)
have revolutionized the treatmentofmetastatic renal cell carcinoma
(mRCC) and have supplanted cytokine therapy as the standard of
care in clinical practice. While targeted therapies have signiﬁcantly
improved patient outcome in terms of progression-free survival and
overall survival, most patients achieve stable disease or a partial
response; the complete remission (CR) rate is much lower and has
been reported to be about 3% with sunitinib in a phase III trial.1 CRs
have primarily been described in case reports/series, with the ma-
jority of patients receiving sunitinib, with or without surgical
intervention.2 CR has been noted in many different metastatic sites,
including adrenal, hepatic, andpancreaticmetastases,withdecrease
in pulmonary metastases being the most common; CR of brain me-
tastases has been much less commonly reported.3 We report here a
case of a clinical and a pathological CR after treatmentwith sunitinib
in apatientwhopresentedwithprimaryRCC in situ in the left kidney
and widely metastatic disease.
Case presentation
A 46-year-old Caucasian male patient presented in March 2006
with left ﬂank pain, micro-hematuria, and a 15-pound weight loss.
A CT scan of the abdomen demonstrated a 10-cm heterogenoush).
Inc. This is an open access article uenhancing mass involving the upper pole of the left kidney. A bi-
opsy of the renal mass conﬁrmed the presence of Fuhrman nuclear
grade 3 clear-cell RCC. The remainder of body imaging demon-
strated multiple sub-centimeter lung nodules, mediastinal aden-
opathy, and femoral and vertebral lytic lesions. As part of a staging
evaluation prior to enrollment on a pre-surgical protocol, MRI of the
brain was obtained and demonstrated a small enhancing mass in
the right medial temporal lobe as well as innumerable sub-
centimeter metastatic lesions throughout the cerebral hemi-
spheres. Given that the patient was neurologically intact, it was
decided to defer whole brain radiation and start systemic therapy
with sorafenib 400 mg twice daily.
At the 16-week restaging visit, the patient was found to have
progression of the primary tumor, multiple new lytic osseous me-
tastases, increase in number and size of pulmonary metastases, and
interval development of new bilobar hepatic metastases. At that
time (August 2006), sorafenib was discontinued and sunitinib was
started at 50 mg daily for 28 days on and 14 days off. At his 6-week
restaging visit from initiation of sunitinib, patient’s disease
responded in the liver and lungs. At the 24-week restaging visit,
there was noted improvement in the size of the brain metastases,
which then resolved entirely by the 30-week restaging visit.
Afterﬁveandhalf yearsof sunitinib therapy, thepatientdeveloped
new-onset hypertension and was hospitalized because of hyperten-
sive crisis. Sunitinib therapy was therefore discontinued (February
2012). Given these adverse events and the achievement of a clinical
and radiographic CR in all metastatic sites (Figs. 1-3), a multidisci-
plinary decisionwasmade for the patient to undergo a cytoreductivender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. T1-weighted contrast-enhanced MRI of the brain: Pre-treatment scan shows an enhancing metastasis with surrounding edema. After systemic treatment, a tiny residual
lesion is visible, consistent with scarring.
Figure 2. -Contrast-enhanced CT of the abdomen: Pre-treatment scan shows a large heterogeneously enhancing, partly calciﬁed, primary mass in the left kidney. Post-treatment
study shows a smaller, homogenously hypodense lesion with calciﬁc rim, suggestive of treatment changes. Ultimately, a nephrectomy was undertaken; on pathology, this mass
showed only necrosis and no active disease.
Figure 3. CT of the pelvis with bone windows: Pre-treatment scan shows a lytic lesion in S1 vertebral body and small lesion in the right iliac bone. Post-treatment scans show a
smaller S1 lesion, not actively lytic, with a sclerotic rim, suggestive of no active disease. The right iliac lesion is no longer evident.
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left radical nephrectomy; pathology reviewof the left kidney showed
necrosis with no viable tumor seen, and negative resection margins.
The patient has been off systemic therapy for close to 3 years and
remains without evidence of disease as of December 2014.
Discussion
There have been few reports in the literature of brain metastases
responding completely to sunitinib in the absence of radiotherapy or
surgical resection. Lim et al performed a retrospective study of six
patients, eachwithmore than twobrainmetastases, and founda near
CR in threepatientswith sunitinib therapyalone;patientswithsupra-
tentorial, asymptomatic, small metastases with no associated hem-
orrhage were good candidates to receive upfront systemic therapy.4
An open-label expanded access trial of sunitinib evaluated 4371 pa-
tients, 7% of whom (321 patients) had baseline brain metastases; the
general safety proﬁle and tolerability of sunitinib was comparable
between patients with brain metastases and the general mRCC pop-
ulation, but outcomes were signiﬁcantly worse for the brain metas-
tases group.5 Furtherdata is needed regarding theoptimal durationof
systemic therapy in exceptional responders to TKIs, and who among
these responders will remain in remission after discontinuation of
therapy. Research is ongoing to characterize the molecular de-
terminants of response and resistance to targeted therapy.
Conclusion
TKIs have revolutionized the treatment of mRCC. While
response rates to ﬁrst-line TKI therapies are approximately 30%,most patients ultimately develop progressive disease and suc-
cumb to their cancer. We report here a patient with clear-cell RCC
who had metastases to bone, liver, lungs, and brain, and achieved
a complete clinical and pathological response to sunitinib. The
patient continues to be disease-free close to 3 years after
discontinuation of therapy. To our knowledge, this is the ﬁrst
report of a patient with both a dramatic complete resolution of
multiple brain metastases with TKI therapy and pathological CR
of primary renal tumor, suggesting cure with TKIs alone is
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